Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Lintzeris

Showing results (161-170 of 196) with videos related to

Pageof 20
Sort By:
Eclinicalmedicine|December 9, 2020
Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort studyGabrielle Campbell, Firouzeh Noghrehchi, Suzanne Nielsen, et al.
Drug and Alcohol Review|September 14, 2021
Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, AustraliaNicholas Lintzeris, Rachel M Deacon, Victoria Hayes, et al.
Journal of Addiction Medicine|November 20, 2019
Consensus and Controversies Between Pain and Addiction Experts on the Prevention, Diagnosis, and Management of Prescription Opioid Use DisorderMark Kraus, Nicholas Lintzeris, Arun Bhaskar, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 23, 2022
Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studiesSuzanne Nielsen, Louisa Picco, Bridin Murnion, et al.
Drug and Alcohol Review|February 19, 2026
Experiences of People Who Discontinue Long-Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, AustraliaLucy J D Peck, Bethany White, Maja Moensted, et al.
Addiction (Abingdon, England)|April 24, 2019
Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorderMichael Frost, Genie L Bailey, Nicholas Lintzeris, et al.
Drug and Alcohol Dependence|April 4, 2017
Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trialAdrian J Dunlop, Amanda L Brown, Christopher Oldmeadow, et al.
Drug and Alcohol Review|April 20, 2022
The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptionsLauren A Monds, Maria Bravo, Llewellyn Mills, et al.
JAMA Psychiatry|January 17, 2014
Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trialDavid J Allsop, Jan Copeland, Nicholas Lintzeris, et al.
Addiction (Abingdon, England)|October 17, 2020
Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian citiesSuzanne Nielsen, Paul Sanfilippo, Vendula Belackova, et al.
Pageof 20

Showing results (161-170 of 196) with videos related to

Sort By:
Pageof 20
Eclinicalmedicine|December 9, 2020
Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort studyGabrielle Campbell, Firouzeh Noghrehchi, Suzanne Nielsen, et al.
Drug and Alcohol Review|September 14, 2021
Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, AustraliaNicholas Lintzeris, Rachel M Deacon, Victoria Hayes, et al.
Journal of Addiction Medicine|November 20, 2019
Consensus and Controversies Between Pain and Addiction Experts on the Prevention, Diagnosis, and Management of Prescription Opioid Use DisorderMark Kraus, Nicholas Lintzeris, Arun Bhaskar, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 23, 2022
Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studiesSuzanne Nielsen, Louisa Picco, Bridin Murnion, et al.
Drug and Alcohol Review|February 19, 2026
Experiences of People Who Discontinue Long-Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, AustraliaLucy J D Peck, Bethany White, Maja Moensted, et al.
Addiction (Abingdon, England)|April 24, 2019
Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorderMichael Frost, Genie L Bailey, Nicholas Lintzeris, et al.
Drug and Alcohol Dependence|April 4, 2017
Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trialAdrian J Dunlop, Amanda L Brown, Christopher Oldmeadow, et al.
Drug and Alcohol Review|April 20, 2022
The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptionsLauren A Monds, Maria Bravo, Llewellyn Mills, et al.
JAMA Psychiatry|January 17, 2014
Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trialDavid J Allsop, Jan Copeland, Nicholas Lintzeris, et al.
Addiction (Abingdon, England)|October 17, 2020
Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian citiesSuzanne Nielsen, Paul Sanfilippo, Vendula Belackova, et al.
Pageof 20